Primary Sclerosing Cholangitis: A Comprehensive Overview
Definition and Pathophysiology
Primary sclerosing cholangitis (PSC) is an immune-mediated chronic cholestatic liver disease characterized by progressive inflammation, fibrosis, and destruction of intrahepatic and/or extrahepatic bile ducts, leading to biliary strictures, cirrhosis, and ultimately liver failure. 1 The disease involves multi-focal bile duct stricturing with beading and irregularity on cholangiography, resulting from cholangiocyte injury triggered by environmental exposures and abnormal immune responses in genetically susceptible individuals 2, 3.
A variant called small duct PSC presents with typical cholestatic biochemistry and histological findings but normal-appearing bile ducts on cholangiography, with an incidence of 0.15 per 100,000 person-years 1.
Epidemiology
General Population
- Prevalence: 8.06 per 100,000 individuals (95% CI 4.75-13.36) 4
- Incidence: 0.892 per 100,000 person-years (95% CI 0.705-1.130), with estimates ranging from 0.91 to 1.3 per 100,000 1, 4
- Geographic variation: Highest in populations of northern European descent 1
- Demographics: More common in men, typically diagnosed between ages 30-40 2
IBD Population
- Overall PSC prevalence in IBD: 15.2 per 1,000 (1.52%) 4
- Ulcerative colitis: 20.6 per 1,000 (2.06%) - significantly higher risk 4
- Crohn's disease: 10.2 per 1,000 (1.02%) 4
- Approximately 70% of PSC patients have concurrent IBD 3, which often precedes PSC development 2
Clinical Presentation
Modes of Presentation
Patients present in several distinct patterns 1:
- Asymptomatic (most common in early disease): Incidental finding of abnormal liver biochemistry
- IBD screening: Biochemical abnormalities detected during routine monitoring of known IBD patients
- Cholestatic symptoms: Jaundice and pruritus
- Bacterial cholangitis: Fever, right upper quadrant pain, jaundice
- Liver failure: Jaundice with hepatic decompensation
- Portal hypertension: Variceal bleeding and/or ascites
- Cholangiocarcinoma: Presenting as malignancy
Symptomatic Disease
When symptomatic, the most common presentations include 1, 2:
- Right upper quadrant abdominal pain
- Pruritus (itching)
- Fatigue
- Jaundice
- Steatorrhea (in advanced disease)
Critical pitfall: Symptoms are rare in early disease, making screening of IBD patients essential 1.
Diagnostic Criteria
Blood Tests
Approximately 75% of PSC patients have abnormal liver biochemistry 1:
Cholestatic pattern (most common):
- Elevated alkaline phosphatase (ALP) - sensitive but not specific
- Elevated γ-glutamyl transpeptidase (GGT)
Elevated bilirubin: Present in 28-40%, marker of poor prognosis 1
Transaminases: AST and ALT often mildly elevated
- AST > ALT ratio suggests cirrhosis and poor prognosis 1
Cirrhosis/portal hypertension indicators:
- Elevated PT/INR
- Low albumin
- Thrombocytopenia
Autoantibodies
- Perinuclear antinuclear cytoplasmic antibody (p-ANCA): Positive in 33-88%, but not specific and not related to disease activity or prognosis 1
- No autoantibodies are diagnostic of PSC 1
- Check ANA, AMA, SMA to exclude alternative diagnoses 1
IgG4 Testing
Measure serum IgG4 to differentiate from IgG4-related sclerosing cholangitis 1:
- Raised serum IgG4 found in 22% of PSC patients
- Elevated IgG4 may indicate more aggressive disease with faster progression to transplantation, though this remains controversial
- May represent either misdiagnosis (IgG4-SC) or aggressive PSC phenotype
Cholangiography
Magnetic resonance cholangiopancreatography (MRCP) is the first-line diagnostic imaging modality 5:
- High sensitivity and specificity
- Non-invasive
- Shows intrahepatic and/or extrahepatic biliary stricturing, beading, and irregularity
Endoscopic retrograde cholangiopancreatography (ERCP) remains important for 5:
- Differentiating PSC from cholangiocarcinoma
- Tissue sampling from strictures
- Superior spatial resolution for subtle bile duct changes
- Therapeutic intervention (balloon dilation, stenting)
Exclusion of Secondary Causes
Before diagnosing PSC, exclude secondary sclerosing cholangitis causes 1, as some respond to medical treatment.
Baseline Evaluation
At diagnosis, perform 6:
- Colonoscopy to establish IBD status (78.8% adherence in real-world practice - suboptimal) 6
- Non-invasive fibrosis staging (only 45% adherence - major gap) 6
Treatment Options
Medical Therapy
No single drug has been proven to improve transplant-free survival 3.
Ursodeoxycholic acid (UDCA):
- Prescribed in approximately 51% of patients at baseline 6
- Median dose: 12.5 mg/kg/day 6
- Can improve ALP and bilirubin concentrations but does not alter disease course 7
- Recent data suggest falling ALP (normalization or <1.5× ULN) stratifies for improved outcome, independent of therapeutic modality 1
Endoscopic Management
For dominant strictures or high-grade strictures 5:
- Balloon dilation is superior to biliary stenting due to lower risk of bacterial cholangitis 5
- Provides symptom relief and may extend survival in patients not eligible for transplantation
- Requires careful patient selection and highly skilled specialists
- Complications include bacterial cholangitis and pancreatitis
Symptomatic Management
Focus on treating symptoms and addressing complications 2:
- Pruritus management
- Nutritional support for fat-soluble vitamin deficiencies
- Treatment of bacterial cholangitis when it occurs
Liver Transplantation
Liver transplantation is the only life-extending therapeutic approach for end-stage PSC 2:
- Required in approximately 40% of patients 2
- Excellent outcomes compared to other transplant indications 2
- PSC is one of the leading indications for liver transplantation 8
Recurrent PSC (rPSC) after transplantation:
- Frequency: 20-30% (ranges from <10% to >50% in various series) 9
- Median time to rPSC: approximately 5 years 9
- Early rPSC (within 5 years): 15-year graft survival drops to 25% 9
- Late rPSC (after 5 years): 15-year graft survival 38% 9
- At least 25% of patients develop recurrent disease in the graft 3
Surveillance Requirements
IBD Surveillance
For PSC patients with IBD, perform colonoscopic surveillance 9, 1:
- Annual colonoscopy (or biennial under complete remission) 9
- Real-world adherence is poor: only 30-35% of PSC-IBD patients undergo annual colonoscopy 6
- Particular attention to risk of:
- Infectious colitis
- Mycophenolate-related colitis (post-transplant)
- Timely consideration for colectomy in refractory cases
Colectomy considerations:
- Pre-emptive colectomy prior to liver transplantation is advised against 9
- Some data suggest colectomy may protect against recurrent PSC post-transplant 9
- Strive for optimal IBD management post-transplant 9
Hepatobiliary Cancer Surveillance
PSC patients require surveillance for cholangiocarcinoma and hepatocellular carcinoma:
- Abdominal imaging: Adherence declines from 74% at Year 1 to 51% by Year 4 6
- CA 19-9 testing: Documented in only 47% over 5-year period 6
- Surveillance strategies for early cholangiocarcinoma detection remain limited 3
Gallbladder Surveillance
Monitor for gallbladder polyps and adenocarcinoma 2.
Prognosis and Complications
Natural History
PSC is a progressive disease with poor prognosis 7:
- Progression to liver cirrhosis is common
- Approximately 40% ultimately require liver transplantation 2
- Natural history varies considerably between patients
Malignancy Risk
Cholangiocarcinoma (CCA):
- Most common malignancy in PSC 2
- Cumulative lifetime risk: 10-20% 2
- Accounts for a large proportion of mortality in PSC 2
Colorectal cancer:
Hepatobiliary cancers:
- Increased risk overall 7
Other Complications
- Bacterial cholangitis
- Dominant strictures requiring intervention
- Portal hypertension with variceal bleeding and ascites
- Hepatic decompensation
- Fat-soluble vitamin deficiencies
Prognostic Markers
- Elevated bilirubin: Marker of poor prognosis 1
- AST > ALT: Indicator of cirrhosis and poor prognosis 1
- Falling ALP: Associated with improved outcome 1
Critical Gaps in Care
Real-world adherence to guideline-based care remains suboptimal in North America 6:
- Baseline colonoscopy to establish IBD status: 78.8% (should be higher)
- Baseline fibrosis staging: 45% (major gap)
- Annual CRC surveillance in PSC-IBD: 30-35% (severely inadequate)
- Hepatobiliary cancer imaging: declining adherence over time
- Socioeconomic factors (lower education, household income) associated with reduced adherence 6
Efforts to standardize care and address socioeconomic barriers are urgently needed 6.
Key Clinical Pitfalls
- Missing early disease: Symptoms are rare early; screen all IBD patients
- Inadequate surveillance: Both colonoscopy and hepatobiliary imaging adherence is poor
- Misdiagnosis: Must exclude IgG4-related sclerosing cholangitis and secondary causes
- Inappropriate UDCA expectations: Does not alter disease course despite biochemical improvement
- Delayed transplant referral: Refer early given lack of effective medical therapy
- Post-transplant IBD management: Requires continued vigilance for complications and optimal control